Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

667
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

4
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
4

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between Diabetes with Drug Use, Family History and Alcohol; Insights from the PERSIAN Cohort Study for Health Service Management :.

Galen medical journal·2026
Same author

Persian Paradigm for Language Cortical Mapping: Development, Feasibility, and Evaluation.

Brain and behavior·2026
Same author

Lead-free layered halide double perovskites with aromatic organic cations for resistive switching memories and artificial synapses.

Materials horizons·2026
Same author

Integrated memristor for mitigating reverse-bias in perovskite solar cells.

Nature·2026
Same author

Evaluating the Effectiveness of Home based versus Comprehensive Cardiac Rehabilitation on Mortality in Myocardial Infarction Survivors.

International journal of preventive medicine·2026
Same author

Social and socioeconomic determinants of health and contraceptive decision-making among women: a cross-sectional study from southeastern Iran.

BMC public health·2025

Related Experiment Video

Updated: Apr 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Imatinib therapy in chronic myelogenous leukemia and thyroid function tests.

Mohammad Ali Mashhadi1, Mahmoud Ali Kaykhaei2, Mahdi Mohammadi1

  • 1Health promotion research center, Zahedan University of Medical Sciences, Zahedan, Iran.

International Journal of Hematology-Oncology and Stem Cell Research
|February 3, 2015
PubMed
Summary

Imatinib therapy for chronic myelogenous leukemia (CML) can alter thyroid function tests, including TSH and Free T3 levels. However, these changes remained within normal clinical ranges during the study period.

Keywords:
Chronic myelogenous leukemiaImatinib mesylateThyroid function tests

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Area of Science:

  • Endocrinology
  • Hematology
  • Pharmacology

Background:

  • Imatinib is a tyrosine kinase inhibitor effective in treating chronic myelogenous leukemia (CML).
  • Potential adverse effects of imatinib on thyroid gland function require further investigation.
  • Previous assessments of thyroid function during imatinib therapy were primarily retrospective.

Purpose of the Study:

  • To prospectively evaluate the impact of imatinib on thyroid function in CML patients.
  • To monitor changes in thyroid hormones and antibodies during imatinib treatment.
  • To identify any clinically significant thyroid abnormalities associated with imatinib therapy.

Main Methods:

  • A prospective study involving 16 newly diagnosed adult CML patients.
  • Measurement of Free T3, Free T4, TSH, Anti-TPO, and Anti-thyroglobulin antibodies.
  • Thyroid function tests were conducted before and at 4 and 12 weeks after imatinib initiation.

Main Results:

  • Significant changes in TSH and Free T3 levels were observed within normal ranges.
  • Anti-thyroglobulin antibody levels also showed statistically significant changes.
  • No significant alterations in Free T4 or Anti-TPO antibody concentrations were detected.

Conclusions:

  • Imatinib therapy can induce statistically significant, yet clinically normal, changes in thyroid function tests.
  • No clinical thyroid abnormalities were observed in patients during the study.
  • Further research with larger cohorts and longer follow-up is recommended.